Business
Medicenna Announces March 31, 2017 Year End Results
Medicenna Announces March 31, 2017 Year End Results Canada NewsWire TORONTO and ...
About this update from Medicenna Therapeutics Corp.
[{"type":"text","content":"\n\n\n\nMedicenna Announces March 31, 2017 Year End Results\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO and HOUSTON, TX, June 16, 2017\n\n\n\nTORONTO and HOUSTON, TX, June 16, 2017 /CNW/ - Medicenna Therapeutics Corp. (\"Medicenna\" or the \"Company\") (TSXV: MDNA), a clinical stage immuno-oncology company, today announced its operational and financial results for the year ended March 31, 2017.\n\n\"The past year has been transformational for Medicenna, achieving several clinical, corporate and financial milestones, with treatment of the first recurrent glioblastoma patient in our Phase 2b clinical trial of MDNA55 being the most significant,\" said Dr. Fahar Merchant, Chairman, President and CEO of Medicenna. \"We extended our cash runway by successfully completing a series of private placements raising $14 million in capital, completed a reverse takeover, began trading on the TSXV and solidified our platform technology following the issuance of three additional patents. We have complemented these milestones by initiating activities related to our pre-clinical pipeline that we believe could generate substantial value to our shareholders for years to come. We look forward to the year ahead and top-line data from the MDNA55 Phase 2b clinical trial.\" \n\nThe following are the achievements and highlights for the year ending March 31, 2017 through to the date hereof:\n\n\nInitiated a Phase 2b clinical trial of MDNA55 for the treatment of recurrent glioblastoma (rGB), the most common and uniformly fatal form of brain cancer, and treated the first patient in April 2017. Medicenna expects to complete enrolment in the clinical study by the end of 2017;\nCompleted a reverse takeover transaction (the \"Transaction\") resulting in its shares trading on the TSX Venture Exchange (TSXV) under the symbol \"MDNA\" in March 2017;\nRaised $14 million through a series of private placement financings and received an advance of USD $5 million in February 2017 of the USD $14.1 million in non‐dilutive funds awarded by the Cancer Prevention and Researc...